会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 91. 发明申请
    • Method of Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II
    • US20190015505A1
    • 2019-01-17
    • US16032482
    • 2018-07-11
    • UNIVERSITY OF MACAU
    • Hang Fai KWOK
    • A61K39/395C07K16/40A61P9/12A61K45/06
    • Angiotensin II (AngII) has been strongly implicated in hypertension and its complications. Evidence suggests the mechanisms by which angiotensin II (AngII) elevates blood pressure and enhances cardiovascular remodeling and damage may be distinct. However, the signal transduction cascade by which AngII specifically initiates cardiovascular remodeling such as hypertrophy and fibrosis remains insufficiently understood. In vascular smooth muscle cells, a metalloproteinase ADAM17 mediates epidermal growth factor receptor (EGFR) transactivation, which may be responsible for cardiovascular remodeling but not hypertension induced by AngII. Thus, the objective of this study was to test the hypothesis that activation of vascular ADAM1.7 is indispensable for vascular remodeling but not for hypertension induced by AngII. Vascular ADAM17 deficient mice and control mice were infused with AngII for 2 weeks. Control mice infused with Angti showed cardiac hypertrophy, vascular medial hypertrophy and perivascular fibrosis. These phenotypes were prevented in vascular ADAM17 deficient mice independent of blood pressure alteration. AngII infusion enhanced ADAM17 expression, EGFR activation and ER stress in the vasculature, which were diminished in ADAM17 deficient mice. Treatment with a human cross-reactive ADAM17 inhibitory antibody also prevented cardiovascular remodeling and ER stress but not hypertension in C57B1/6 mice infused with AngII. In vitro data further supported these findings. In conclusion, vascular ADAM17 mediates AngThinduced cardiovascular remodeling via EGFR activation independent of blood pressure regulation. ADAM17 seems to be a unique therapeutic target for the prevention of hypertensive complications.
    • 98. 发明授权
    • Gain-boosted N-path bandpass filter
    • 增益N路径带通滤波器
    • US09374063B1
    • 2016-06-21
    • US14726881
    • 2015-06-01
    • University of Macau
    • Pui-In MakZhicheng LinRui Paulo da Silva Martins
    • H03H19/00H03H11/04H03H11/12
    • H03H11/0472H03B5/1237H03B5/1246H03B2202/06H03F1/0205H03F3/19H03F3/45076H03F2200/294H03F2200/451H03H11/1291H03H19/002H03H19/004H03H2011/0483H03H2210/025H04B1/16H04B1/1638
    • The present invention discloses a gain-boosted N-path SC bandpass filter (GB-BPF) with a number of sought features. It is based on a transconductance amplifier (Gm) with an N-path SC branch as its feedback network, offering 1) double RF filtering at the input and output of the Gm in one step; 2) customized passband gain and bandwidth with input-impedance match, and 3) reduced physical capacitance thanks to the loop gain offered by Gm. All have been examined using a RLC model of the SC branch before applying the linear periodically time-variant (LPTV) analysis to derive the R, L and C expressions and analytically study the harmonic selectivity, harmonic folding and noise. The latter reveals that: 1) the noise due to the switches is notched at the output, allowing smaller switches to save the LO power; and 2) the noises due to the source resistance and Gm are narrowband at the output, reducing the folded noise during harmonic mixing.
    • 本发明公开了一种具有多个寻求特征的增益增强的N路径SC带通滤波器(GB-BPF)。 它基于具有N路径SC分支作为其反馈网络的跨导放大器(Gm),在一步中在Gm的输入和输出处提供1)双RF滤波; 2)通过输入阻抗匹配定制通带增益和带宽,3)由于Gm提供的环路增益,3)降低了物理电容。 在应用线性周期时变(LPTV)分析之前,已经使用SC分支的RLC模型来检验所有的R,L和C表达式,并分析研究谐波选择性,谐波折叠和噪声。 后者显示:1)由于开关引起的噪声在输出端被切口,允许较小的开关节省LO功率; 和2)由于源电阻而产生的噪声,Gm在输出处是窄带,减少了谐波混合期间的折叠噪声。